<DOC>
	<DOCNO>NCT00646087</DOCNO>
	<brief_summary>Depression wide spread illness . Depression contribute significantly national health care cost . While number type treatment use depression expand year , even increase range option , response rate , define number subject 50 % reduction depressive symptom , estimate around 65 % . This randomized clinical trial examine frequency treatment ketamine patient treatment-resistant depression TRD without psychosis . It compare two mode ketamine treatment ; every day ketamine , versus two active four placebo treatment period 12 day .</brief_summary>
	<brief_title>Ketamine Frequency Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Age 30 65 Major depressive disorder without psychotic feature confirm structured clinical diagnostic interview , SCID . Treatment resistant depression define use Antidepressant Treatment History Form ( ATHF ) HDRS 21 score &gt; 18 Female participant childbearing potential must use medically accept mean contraception ( birth control pill , spermicidal barrier ) Ability concur medication standardization regiment ( section outpatient Physically healthy ( chronic disease ; normal CBC , BMP , AST , ALT , UA ) Competent give inform consent require test examination sign consent document Bipolar disorder Psychosis psychotic disorder define DSMIV criterion Serious imminent threat suicide Pregnant nursing female Presence serious unstable medical illness include hepatic , renal , gastrointestinal , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease , abnormal laboratory test ( CBC , BMP , AST , ALT , UA ) Uncontrolled hypertension History CVA Treatment St. Johns wort , tramadol , phentolamine , naloxone , anticholinergic medication Alcohol illicit drug abuse 6 month ( evidence UDS ) Currently involve clinical trial use experimental medication within last 30 day Hypersensitivity ketamine product</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>